Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 7, Issue 10, 2013, Pages 769-779

  Mocci, Giammarco ^a   Marzo, Manuela ^b   Papa, Alfredo ^b   Armuzzi, Alessandro ^b   Guidi, Luisa ^b  

^a BROTZU HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anti TNF; IBD; Skin manifestations

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; PARACETAMOL; TUMOR NECROSIS FACTOR INHIBITOR;

ABSCESS; ADVERSE DRUG REACTION; APOPTOSIS; BASAL CELL CARCINOMA; BRONCHOSPASM; CANDIDIASIS; CELLULITIS; COOLING; CYTOMEGALOVIRUS INFECTION; DERMATITIS; DRUG SAFETY; DYSPNEA; ECZEMA; ENTERITIS; ERYSIPELAS; ERYTHEMA; ERYTHEMA MULTIFORME; FEVER; FLUSHING; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HYPOTENSION; INFLAMMATORY CELL; INFUSION RELATED REACTION; INJECTION SITE IRRITATION; INJECTION SITE REACTION; LUPUS LIKE SYNDROME; MELANOMA; MOLLUSCUM CONTAGIOSUM; NAUSEA; NON MELANOMA SKIN CANCER; PAPILLOMAVIRUS INFECTION; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN BRUISING; SKIN CANCER; SKIN INFECTION; SKIN MANIFESTATION; SKIN PAIN; SKIN PRURITUS; SKIN REDNESS; SKIN SWELLING; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; TH2 CELL; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VASCULITIS;

ANTI-TNF; IBD; SKIN MANIFESTATIONS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ERUPTIONS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; LUPUS ERYTHEMATOSUS, CUTANEOUS; POLYETHYLENE GLYCOLS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN DISEASES, INFECTIOUS; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884138822     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.01.009     Document Type: Review

References (126)

1. Tracey D., Klareskog L., Sasso E.H., et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
2. Product websites. As found on product websites and confirmed with companies: , ,. cimzia.com/Default1.asp, (all websites accessed 30 May 2011). http://www.
3. Van Assche G., Lewis J.D., Lichtenstein G.R., et al. The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011, 106:1594-1602.
4. Kerbleski J.F., Gottlieb A.B. Dermatological complications and safety of anti-TNF treatments. Gut 2009, 58(8):1033-1039.
5. Nagy G., Lukàcs K., Sziray A., et al. Adverse events during biological therapy: focusing on dermatological side effects. Orv Hetil 2011, 152(6):212-220.
6. Pichler W.J. Adverse side-effects to biological agents. Allergy 2006, 61(8):912-920.
7. Flendrie M., Vissers W.H., Creemers M.C., et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005, 7:R666-R676.
8. Lee H.H., Song I.H., Friedrich M., et al. Cutaneous side effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007, 156:486-491.
9. Llao J., Gomez-Pastrana B., Gordillo J., et al. Skin lesions in patients with inflammatory bowel disease treated with immunomodulators and/or anti-tumor necrosis factor. J Crohns Colitis 2011, P223. [5:106].
10. Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
11. US Food and Drug Administration. FDA labels for TNF inhibitors: infliximab, ; adalimumab, 125057s114lbl.pdf; etanercept, ; certolizumab pegol, ; (all websites accessed 1 November 2008). http://www.cimzia.com/pdf/CIMZIA%20PI%20032008.pdf.
12. Steenholdt C., Svenson M., Bendtzen K., et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 34:51-58.
13. Miehsler W., Novacek G., Wenzl H., et al. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis 2010, 4:221-256.
14. Vermeire S., Van A.G., Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol 2009, 23:101-112.
15. Centocor Inc. Centocor data. Inquiry Number 1-729933475. Published 26 January 2009, and released to authors.
16. Maggi E., Vultaggio A., Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011, 7:55-63.
17. Ducharme J., Pelletier C., Zacharias R. The safety of infliximab infusions in the community setting. Can J Gastroenterol 2010, 24(5):307-311.
18. Cheifetz A., Smedley M., Martin S., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003, 98:1315-1324.
19. Lequerre' T., Vittecoq O., Klemmer N., et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 2006, 33:1307-1314.
20. Cheifetz A., Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005, 72:250-256.
21. Lees C.W., Ali A., Thompson A., et al. The safety profile of anti-TNF therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2009, 29:286-297.
22. Colombel J.F., Loftus E.V., Tremaine W.J., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004, 126:19-31.
23. Wasserman M.J., Weber D.A., Guthrie J.A., et al. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol 2004, 31:1912-1917.
24. Sany J., Kaiser M.J., Jorgensen C., et al. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis 2005, 64:1647-1649.
25. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002, 359:1541-1549.
26. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
27. Moss A.C., Fernandez-Becker N., Kim K.J., et al. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther 2008, 2:221-227.
28. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
29. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
30. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295(19):2275-2285.
31. Strangfeld A., Listing J. Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 2006, 20(6):1181-1195.
32. Listing J., Strangfeld A., Kary S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52(11):3403-3412.
33. Dixon W.G., Symmons D.P., Lunt M., et al. British Society for Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007, 56(9):2896-2904.
34. Askling J., Fored C.M., Brandt L., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF-antagonists. Ann Rheum Dis 2007, 66(10):1339-1344.
35. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor neutralizing agent. N Engl J Med 2001, 345:1098-1104.
36. Velayos F.S., Sandborn W.J. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004, 10:657-660.
37. Slifman N.R., Gershon S.K., Lee J.H., et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003, 48:319-324.
38. Peyrin-Biroulet L., Deltenre P., De Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
39. Lichtenstein G., Feagan B., Cohen R., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
40. Lichtenstein G., Cohen R., Feagan B., et al. Safety of infliximab and other Crohn's disease therapies: TREAT registry data with 24,575 patient years of follow-up. Am J Gastroenterol 2008, 103:S436.
41. Cabou C., Bagheri H., Cantagrel A., et al. Retrospective analysis of adverse effects of infliximab in a hospital rheumatology service. Therapie 2003, 58:457-462.
42. Dixon W.G., Watson K., Lunt M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:2368-2376.
43. Kroesen S., Widmer A.F., Tyndall A., et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003, 42:617-621.
44. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.
45. Doran M.F., Crowson C.S., Pond G.R., et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002, 46:2294-2300.
46. Rahier J.F., Ben-Horin S., Chowers Y., et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.
47. Bernatsky S., Hudson M., Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:1157-1160.
48. Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
49. Wolfe F., Caplan L., Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006, 54:628-634.
50. Stuck A.E., Minder C.E., Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989, 11:954-963.
51. Shale M.J., Seow C.H., Coffin C.S., et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010, 31:20-34.
52. Wendling D., Streit G., Toussirot E., et al. Herpes zoster in patients taking TNF-alpha antagonists for chronic inflammatory joint disease. Joint Bone Spine 2008, 75:540-543.
53. Strangfeld A., Listing J., Herzer P., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301:737-744.
54. Hambleton S., Gershon A.A. Preventing varicella-zoster disease. Clin Microbiol Rev 2005, 18:70-80.
55. Schiff M.H., Burmester G.R., Kent J.D., et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:889-894.
56. Georgala S., Katoulis A.C., Kanelleas A., et al. Letter: Human papilloma virus and molluscum contagiosum lesions related to infliximab therapy for psoriasis: a case series. Dermatol Online J 2012, 18(4):9.
57. Antoniou C., Kosmadaki M.G., Stratigos A.J., et al. Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology 2008, 216(4):364-365.
58. Somasekar A., Alcolado R. Genital condylomata in a patient receiving infliximab for Crohn's disease. Postgrad Med J 2004, 80(944):358-359.
59. Hutfless S., Fireman B., Kane S., et al. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2008, 28(5):598-605.
60. Tzu J., Kerdel F. From conventional to cutting edge: the new era of biologics in treatment of psoriasis. Dermatol Ther 2008, 21:131-141.
61. Chaudhari U., Romano P., Mulcahy L.D., et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001, 357:1842-1847.
62. Collamer A.N., Guerrero K.T., Henning J., et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008, 59:996-1001.
63. Ko J.M., Gottlieb A.B., Kerbleski J.F. Induction and exacerbation of psoriasis with TNF blockade therapy. A review and analysis of 127 cases. J Dermatol Treat 2009, 20:100-108.
64. Steinwurz F., Denadai R., Saad-Hossne R., et al. Infliximab-induced psoriasis during therapy for Crohn's disease. J Crohns Colitis 2012, 6(5):610-616.
65. Cleynen I., Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 2012, 9(9):496-503.
66. Fiorino G., Allez M., Malesci A., et al. Review article: anti TNFalpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009, 29:921-927.
67. Medkour F., Babai S., Chanteloup E., et al. Development of diffuse psoriasis with alopecia during treatment of Crohn's disease with infliximab. Gastroenterol Clin Biol 2010, 34:140.
68. Passarini B., Infusino S.D., Barbieri E., et al. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor necrosis-factor. Antibody Ther Dermatol 2007, 215:295-300.
69. Thurber M., Feasel A., Stroehlein J., et al. Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004, 3:439-440.
70. Guerra I., Algaba A., Pérez-Calle J.L., et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis 2012, 6(5):518-523.
71. Harris M.D., Richards R. First case report of adalimumab-induced psoriasis in Crohn's disease. Am J Gastroenterol 2009, 104:792-793.
72. El Shabrawi-Caelen L., La Placa M., Vincenzi C., et al. Adalimumab induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers. Inflamm Bowel Dis 2010, 16:182-183.
73. Verea M.M., Del Pozo J., Yebra-Pimentel M.T., et al. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004, 38:54-57.
74. Peramiquel L., Puig L., Dalmau J., et al. Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Dermatol 2005, 30:713-714.
75. Pirard D., Arco D., Debrouckere V., et al. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology 2006, 213:182-186.
76. González-López M.A., Blanco-Alonso R., Yáñez-Díaz S., et al. Psoriasis induced by infliximab: a paradoxical event. Med Clin Barc 2006, 127:316.
77. Adams D.R. Infliximab associated new-onset psoriasis. J Drugs Dermatol 2006, 5:178-179.
78. Cohen J.D., Bournerias I., Buffard V., et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 2007, 34:380-385.
79. Angelucci E., Cocco A., Viscido A., et al. Another paradox in Crohn's disease: newonset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm Bowel Dis 2007, 13:1059-1061.
80. Bruzzese V. Diffused suberitrodermic psoriasis induced by infliximab. Reumatismo 2007, 59:328-331.
81. Umeno J., Matsumoto T., Jo Y., et al. Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2007, 13:1188-1189.
82. Severs G.A., Lawlor T.H., Purcell S.M., et al. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients. Cutis 2007, 80:231-237.
83. Sladden M.J., Clarke P.J., Wettenhall J. Infliximab-induced palmoplantar pustulosis in a patient with Crohn disease. Arch Dermatol 2007, 143:1449.
84. Takahashi H., Hashimoto Y., Ishida-Yamamoto A., et al. Psoriasiform and pustular eruption induced by infliximab. J Dermatol 2007, 34:468-472.
85. Wollina U., Hansel G., Koch A., et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthema: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008, 9:1-14.
86. Richetta A., Mattozzi C., Carlomagno V., et al. A case of infliximab-induced psoriasis. Dermatol Online J 2008, 14:9.
87. English P.L., Vender R. Occurrence of plantar pustular psoriasis during treatment with infliximab. Cutan Med Surg 2009, 13:40-42.
88. Manni E., Barachini P. Psoriasis induced by infliximab in a patient suffering from Crohn's disease. Int J Immunopathol Pharmacol 2009, 22:841-844.
89. Sfikakis P.P., Iliopoulos A., Elezoglou A., et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005, 52:2513-2518.
90. Palucka A.K., Blanck J.P., Bennett L., et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 2005, 102:3372-3377.
91. Cullen G., Kroshinsky D., Cheifetz A.S., et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011, 11-12:1318-1327.
92. Denadai R., Teixeira F.V., Saad-Hossne R. The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?. Arq Gastroenterol 2012, 49(2):172-176.
93. Denadai R., Teixeira F.V., Steinwurz F., et al. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: A systematic literature review based on 222 cases. J Crohns Colitis 2012 Sep 6, [epub ahead of print].
94. Iborra M., Beltràn B., Bastida G., et al. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. J Crohns Colitis 2010, 5:157-161.
95. Baumgart D.C., Grittner U., Steingräber A., et al. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis 2011, 17(12):2512-2520.
96. Rahier J.F., Buche S., Peyrin-Biroulet L., et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumour necrosis factor therapy. Clin Gastroenterol Hepatol 2010, 12:1048-1055.
97. Williams V.L., Cohen P.R. TNF-alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF-alpha antagonists. Int J Dermatol 2011, 50:619-625.
98. Wetter D.A., Davis M.D.P. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009, 84:979-984.
99. Ramos-Casals M., Brito-Zeròn P., Soto M.J., et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008, 22(5):847-861.
100. De Bant M., Sibilia J., Le Loet X., et al. With the Club Rhumatismes Inflammation. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French survey. Arthritis Res Ther 2005, 7:R545-R551.
101. Williams E.L., Gadola S., Edwards C.J. Anti-TNF-induced lupus. Rheumatology 2009, 48:716-720.
102. Marzano A.V., Vezzoli P., Crosti C. Drug induced lupus: an update on its dermatological aspects. Lupus 2009, 18:935-940.
103. Statkute L., Ruderman E.M. Novel TNF antagonists for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 2010, 19:105-115.
104. Bout-Tabaku S., Rivas-Chacon R., Restrepo R. Systemic lupus erythematosus in a patient with etanercept for polyarticular juvenile rheumatoid arthritis. J Rheumatol 2007, 34:2503-2504.
105. Ferraccioli G., Mecchia F., Di Poi E., et al. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002, 62:358-361.
106. Via C.S., Shustov A., Rus V., et al. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001, 167:6821-6826.
107. Costa M.F., Said M.R., Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008, 37:381-387.
108. Ramos-Casals M., Brito-Zeron P., Munoz S., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007, 86:242-251.
109. De Rycke L., Baeten D., Kruithof E., et al. The effect of TNF-alpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005, 14:931-937.
110. Atzeni F., Turiel M., Capsoni F., et al. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci 2005, 1051:559-569.
111. Vermeire S., Noman M., Van Assche G., et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003, 125(1):32-39.
112. Kocharla L., Mongey A.B. Is the development of drug related lupus a contraindication for switching from one TNF-alpha inhibitor to another?. Lupus 2009, 18:169-171.
113. Cush J.J. Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol 2004, 22:S141-S147.
114. US Food Drug Administration Tumor Necrosis Factor alpha (TNF-a) antagonists [infliximab (marketed as REMICADE), etanercept (marketed as ENBREL), and adalimumab (marketed as HUMIRA)]: Serious Skin Reactions. FDA Drug Saf Newsl 2008, 1(2). [http://www.fda.gov/cder/dsn/2008_winter/postmarketing.htm#tnf (accessed 15 December 2008)].
115. Beuthien W., Mellinghoff H.U., von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 2004, 50:1690-1692.
116. Kain T., MacGregor D., Buchanan R.R., et al. Erythema multiforme with tumour necrosis factor inhibitors: a class effect?. Ann Rheum Dis 2008, 67:899-900.
117. Askling J., Fahrbach K., Nordstrom B., et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011, 20(2):119-130.
118. Long M.D., Martin C.F., Pipkin C.A., et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012, 2:390-399.
119. Burmester G.R., Panaccione R., Gordon K.B., et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2012 Jul 6, 10.1136/annrheumdis-2011-201244.
120. Le Blay P., Mouterde G., Barnetche T., et al. Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. Clin Exp Rheumatol 2012, 30(5):756-764.
121. Stern R.S., Leibman E.J., Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 1998, 90:1278-1284.
122. Stern R.S., Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow up Study. Cancer 1994, 73:2759-2764.
123. Marcil I., Stern R.S. Squamous-cell cancer of the skin in patients given PUVA and cyclosporine: Nested cohort cross-over study. Lancet 2001, 358:1042-1045.
124. Paul C.F., Ho V.C., McGeown C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study. J Invest Dermatol 2003, 120:211-216.
125. Setshedi M., Epstein D., Winter T.A., et al. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2011, 27:385-389.
126. Peyrin-Biroulet L., Khosrotehrani K., Carrat F., et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011, 5:1621-1628.